AIDS Healthcare Foundation Challenges Gilead Over AIDS Drug Price Gouging of U.S. Government Programs on Stribild
February 1, 2013
The AIDS Healthcare Foundation (AHF) reported that Gilead Sciences, Inc. charges U.S. HIV patients $28,500 per year for the new HIV drug Stribild, in comparison to $16,600 per patient per year in Canada and European countries with price controls. AHF president Michael Weinstein questioned why Gilead was willing to charge U.S. government programs like ADAP and U.S. HIV patients 42 percent more per patient, per year than price-controlled countries with stronger economies.
Rock Hill Herald Online (Rock Hill, S.C.)
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)